This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Almawi, W. Y.
Right arrow Articles by Irani-Hakime, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Almawi, W. Y.
Right arrow Articles by Irani-Hakime, N.

 Previous Article

Clinical and Vaccine Immunology, November 2006, p. 1296-1298, Vol. 13, No. 11
1071-412X/06/$08.00+0     doi:10.1128/CVI.00206-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Association of Selective HLA Class II Susceptibility-Conferring and Protective Haplotypes with Type 2 Diabetes in Patients from Bahrain and Lebanon{triangledown}

Wassim Y. Almawi,1* Saria F. Wakim-Ghorayeb,2 Mona R. Arekat,3 Pierre Najm,2 Sose H. Keleshian,4 Nasreen Al-Sayed,3 Bruno Blanchon,3 Hanady R. Samaha,2 and Noha Irani-Hakime2

College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Bahrain,1 St. Georges University Hospital, Beirut, Lebanon,2 Joslin Diabetes Center-Bahrain, Manama, Bahrain,3 Haigazian University, Beirut, Lebanon4

Received 3 June 2006/ Returned for modification 17 July 2006/ Accepted 12 September 2006


arrow
ABSTRACT
 
The association of HLA class II with type 2 diabetes (T2DM) was investigated in Bahraini and Lebanese subjects. DRB1*070101 (Lebanese and Bahraini) and DQB1*0201 (Lebanese) were susceptibility-conferring alleles, and unique susceptibility-conferring/protective haplotypes were found in both patient groups. Regression analysis confirmed that DRB1*070101-DQB1*0201 (Bahraini) and DRB1*110101-DQB1*0201 (Lebanese) were susceptibility-conferring haplotypes.


arrow
TEXT
 
Type 2 (non-insulin-dependent) diabetes mellitus (T2DM) is the most common diabetes form (19), and susceptibility to it is determined by environmental and genetic factors (9, 19), the latter being complex and poorly defined (5, 19). While the association of HLA class II genes in type 1 diabetes pathogenesis was reported for several ethnicities (1, 14), studies on HLA class II association with T2DM provided inconsistent results, since an association (16), no association (7), or a weak link between HLA class II and T2DM has been reported. A number of studies focused on the association of HLA with T2DM morbidity and mortality (17), highlighted by increased frequency of HLA-DR3 and -DR4 in islet cell autoantibody (ICA)-positive patients refractory to oral anti-diabetic drugs as reported by some (11) but not others (20), and association of HLA-DRB1*1502 with T2DM in anti-glutamic acid decarboxylase (GAD)-positive patients (10).

We previously reported on the distribution of HLA class II alleles and haplotypes among T2DM patients in the Bahraini population (16), an Arab Peninsula population with a high prevalence (24% of the adult population) of T2DM (2). In view of the heterogeneity of Arabs with distinct ethnic backgrounds and racial origins (3), this study addresses the association of HLA-DRB1 and HLA-DQB1 haplotypes with T2DM in Bahraini and Lebanese Arabs.

T2DM patients comprised 115 Lebanese (59 males and 56 females; mean age, 55.2 ± 13.5 years) and 110 Bahraini (59 males and 51 females; mean age, 52.3 ± 9.6 years) unrelated patients. Exclusion criteria included other types of diabetes, autoimmune diseases, and positive anti-GAD, anti-protein tyrosine phosphatase-related protein (IA-2), or ICA autoantibody responses. Family history of diabetes (80/110 Bahraini patients and 77/115 Lebanese patients) or body mass index did not influence selection of subjects. The control group included 121 Lebanese (57 males and 64 females; mean age, 54.5 ± 13.8 years) and 154 Bahraini (79 males and 75 females; mean age, 52.9 ± 9.0 years) subjects with normal fasting/random glucose levels and no known personal or family history of diabetes. Demographic details, which included duration, first-degree family history, complications, and treatment for diabetes, were recorded. The Arabian Gulf University Ethics Committee approved the study (which was done according to Helsinki guidelines), and informed consent was obtained from all participants.

Total genomic DNA was extracted from EDTA-anticoagulated venous blood by the phenol-chloroform method. HLA-DRB1 and HLA-DQB1 gene alleles were analyzed using the PCR sequence-specific priming (SSP) technique, using an SSP2L HLA class II genotyping kit according to the manufacturer's specifications (One Lambda, Thousand Oaks, CA). Allele frequencies were determined by the gene counting method, and haplotype frequencies were determined by the maximum likelihood method, using the Arlequin (version 2.000) population analysis software. P values were corrected for the number of alleles tested (Pc) using Bonferroni's inequality method; significance was determined at a P value of <0.05.

Significant DRB1 and DQB1 allelic differences were seen between Lebanese and Bahraini T2DM patients and controls. When Bonferroni's correction was applied, DRB1*070101 was significantly more common in both patient groups. While DQB1*0201 was significantly more common among Lebanese patients, none of the DQB1 loci were found to be significantly different between Bahraini patients and controls (Table 1). DRB1-DQB1 haplotype analysis showed that the frequency of DRB1*110101-DQB1*0201 was higher, while the frequencies of DRB1*040101-DQB1*050101, DRB1*110101-DQB1*030101, DRB1*130101-DQB1*060101, and DRB1*140101-DQB1*050101 were lower in Lebanese patients than in controls (Table 2). The frequencies of DRB1*040101-DQB1*0302 and DRB1*070101-DQB1*0201 were higher, while the frequency of DRB1*110101-DQB1*0201 was lower in Bahraini patients than in controls (Table 2). Logistic regression analysis demonstrated, after controlling for confounding variables, that DRB1*070101-DQB1*0201 and DRB1*110101-DQB1*0201 served a dominant role among Bahraini and Lebanese subjects, respectively (Table 3). Other haplotypes were rejected according to the model employed.


View this table:
[in this window]
[in a new window]
  		TABLE 1. HLA-DRB1* allele distribution among T2DM patients and controlsa


View this table:
[in this window]
[in a new window]
  		TABLE 2. DRB1*-DQB1* haplotype distribution


View this table:
[in this window]
[in a new window]
  		TABLE 3. Multinomial regression analysisa

Unique susceptibility-conferring and protective HLA class II haplotypes were seen among Bahraini and Lebanese T2DM patients, with DR7- and DR4-containing (Bahraini) as well as DR11-containing (Lebanese) haplotypes being positively associated with T2DM. Whereas DR4-containing haplotypes conferred susceptibility among Bahraini patients, they were protective among their Lebanese counterparts. DRB1*110101-DQB1*0201 served a susceptibility-conferring role among Lebanese patients but was largely protective among Bahraini patients. The susceptibility conferred by DRB1*040101-DQB1*0302 and DRB1*070101-DQB1*0201 haplotypes among Bahraini subjects confirmed our previous finding (16), with key differences between the two studies, as DRB1*160101-DQB1*050101 was reported earlier to be protective and DRB1*150101-DQB1*060101 and DRB1*070101-DQB1*050101 were reported to confer susceptibility (16). This was largely due to the larger sample analyzed here (110 patients versus 89 patients).

DRB1*040101-DQB1*0302 conferred disease susceptibility in Bahraini patients, in agreement with previous studies on Caucasian (6) and non-Caucasian (8, 12) patients, but in disagreement with others which suggested that DR4 was protective (17). This may be due to ethnic background, patient selection, and sample size. In contrast to the case for Bahrainis, DRB1*040101-DQB1*0302 was neutral among Lebanese patients due to the high prevalence of DRB1*04 among healthy Lebanese (3) and other Mediterranean populations (15). DRB1*110101 was positively or negatively associated with T2DM when present with DQB1*0201 or DQB1*030101, respectively, suggesting that DRB1*110101 did not influence the disease susceptibility, which apparently resided in the DQB1 allele it associated with (18).

While DRB1*070101 was the susceptibility allele in both Lebanese and Bahraini patients, DQB1*0201 was present at higher frequency among Lebanese patients than among Bahraini patients due to the high prevalence of DQB1*0201 among healthy Bahrainis (3). Regression analysis confirmed that DRB1*070101-DQB1*0201 (Bahrain) or DRB1*110101-DQB1*0201 (Lebanon) was a risk factor for T2DM, indicating that HLA class II genotype influenced T2DM pathogenesis in these communities. While the association of specific HLA genotypes with T2DM reportedly disappeared after controlling for GAD or ICA levels (13), this does not appear to be the case here, as all patients were GAD and ICA negative.

While the mechanisms underlying these associations remain to be seen, it is possible that the association of DRB1-DQB1 haplotypes with T2DM and its complications may reside in differential affinity to antigenic fragments presented by each haplotype (4). Susceptibility-conferring haplotypes may bind to and present specific antigens, thereby precipitating hypoglycemia, while "protective" haplotypes may have reduced or no affinity for such antigens. A larger study which addresses class II genotype distribution among T2DM from other communities with a high T2DM prevalence, together with functional association with T2DM complications and response to therapy, are needed to confirm the association of HLA class II with T2DM.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Medical Biochemistry, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 22979, Manama, Bahrain. Phone: 973-39717118. Fax: 973-17271090. E-mail: wyalmawi{at}yahoo.co.uk. Back

{triangledown} Published ahead of print on 20 September 2006. Back


arrow
REFERENCES
 
    1
  1. Al-Jenaidi, F. A., S. F. Wakim-Ghorayeb, A. Al-Abbasi, M. R. Arekat, N. Irani-Hakime, P. Najm, K. Al-Ola, A. A. Motala, and W. Y. Almawi. 2005. Contribution of selective HLA-DRB1/DQB1 alleles and haplotypes to the genetic susceptibility of type 1 diabetes among Lebanese and Bahraini Arabs. J. Clin. Endocrinol. Metab. 90:5104-5109.[Abstract/Free Full Text]
    2. 2
  2. Al-Mahroos, F., and P. M. McKeigue. 1998. High prevalence of diabetes in Bahrainis. Associations with ethnicity and raised plasma cholesterol. Diabetes Care 21:936-942.[Abstract]
    3. 3
  3. Almawi, W. Y., M. Busson, H. Tamim, E. M. Al-Harbi, R. R. Finan, S. F. Wakim-Ghorayeb, and A. A. Motala. 2004. HLA class II profile and distribution of HLA-DRB1 and HLA-DQB1 alleles and haplotypes among Lebanese and Bahraini Arabs. Clin. Diagn. Lab. Immunol. 11:770-774.
    4. 4
  4. Bach, J. M., H. Otto, G. T. Nepom, G. Jung, H. Cohen, J. Timsit, C. Boitard, and P. M. van Endert. 1997. High affinity presentation of an autoantigenic peptide in type I diabetes by an HLA class II protein encoded in a haplotype protecting from disease. J. Autoimmun. 10:375-386.[CrossRef][Medline]
    5. 5
  5. Barroso, I. 2005. Genetics of type 2 diabetes. Diabet. Med. 22:517-535.[CrossRef][Medline]
    6. 6
  6. Bottazzo, G. F., E. Bosi, C. A. Cull, E. Bonifacio, M. Locatelli, P. Zimmet, I. R. Mackay, and R. R. Holman. 2005. IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). Diabetologia 48:703-708.[CrossRef][Medline]
    7. 7
  7. Cerna, M., P. Novota, K. Kolostova, P. Cejkova, E. Zdarsky, D. Novakova, P. Kucera, J. Novak, and M. Andel. 2003. HLA in Czech adult patients with autoimmune diabetes mellitus: comparison with Czech children with type 1 diabetes and patients with type 2 diabetes. Eur. J. Immunogenet. 30:401-407.[CrossRef][Medline]
    8. 8
  8. Dyck, R., C. Bohm, and H. Klomp. 2003. Increased frequency of HLA A2/DR4 and A2/DR8 haplotypes in young Saskatchewan aboriginal people with diabetic end-stage renal disease. Am. J. Nephrol. 23:178-185.[CrossRef][Medline]
    9. 9
  9. Egede, L. E., and S. Dagogo-Jack. 2005. Epidemiology of type 2 diabetes: focus on ethnic minorities. Med. Clin. N. Am. 89:949-975.[Medline]
    10. 10
  10. Fukui, M., K. Nakano, N. Nakamura, E. Maruya, H. Saji, H. Obayashi, K. Ohta, M. Ohta, H. Mori, S. Kajiyama, S. Wada, Y. Kida, K. Kosaka, M. Deguchi, H. Shigeta, Y. Kitagawa, and M. Kondo. 1998. HLA-DRB1 alleles contribute to determining the prognosis of Japanese diabetes mellitus positive for antibodies to glutamate decarboxylase. J. Clin. Immunol. 18:89-92.[CrossRef][Medline]
    11. 11
  11. Groop, L., A. Miettinen, P. H. Groop, S. Meri, S. Koskimies, and G. F. Bottazzo. 1988. Organ-specific autoimmunity and HLA-DR antigens as markers for beta-cell destruction in patients with type II diabetes. Diabetes 37:99-103.[Abstract]
    12. 12
  12. Hamaguchi, K., A. Kimura, Y. Kusuda, T. Yamashita, M. Yasunami, M. Takahasi, N. Abe, and H. Yoshimatsu. 2004. Clinical and genetic characteristics of GAD-antibody positive patients initially diagnosed as having type 2 diabetes. Diabetes Res. Clin. Pract. 66:163-171.[CrossRef][Medline]
    13. 13
  13. Horton, V., I. Stratton, G. F. Bottazzo, M. Shattock, I. Mackay, P. Zimmet, S. Manley, R. Holman, R. Turner, et al. 1999. Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB genotypes (UKPDS 43). Diabetologia 42:608-616.[CrossRef][Medline]
    14. 14
  14. Kawabata, Y., H. Ikegami, Y. Kawaguchi, T. Fujisawa, M. Shintani, M. Ono, M. Nishino, Y. Uchigata, I. Lee, and T. Ogihara. 2002. Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to type 1 diabetes. Diabetes 51:545-551.[Abstract/Free Full Text]
    15. 15
  15. Kwon, O. J., C. Brautbar, N. Weintrob, E. Sprecher, C. Saphirman, K. Bloch, O. Pinhas-Hamiel, S. Assah, P. Vardi, and S. Israel. 2001. Immunogenetics of HLA class II in Israeli Ashkenazi Jewish, Israeli non-Ashkenazi Jewish, and in Israeli Arab IDDM patients. Hum. Immunol. 62:85-91.[CrossRef][Medline]
    16. 16
  16. Motala, A. A., M. Busson, E. M. Al-Harbi, M. A. Khuzam, E. M. Al-Omari, M. R. Arekat, and W. Y. Almawi. 2005. Susceptible and protective human leukocyte antigen class II alleles and haplotypes in Bahraini type 2 (non-insulin-dependent) diabetes mellitus patients. Clin. Diagn. Lab. Immunol. 12:213-217.
    17. 17
  17. Perez-Luque, E., C. Alaez, J. M. Malacara, M. E. Garay, M. E. Fajardo, L. E. Nava, and C. Gorodezky. 2003. Protective effect of DRB1 locus against type 2 diabetes mellitus in Mexican Mestizos. Hum. Immunol. 64:110-118.[CrossRef][Medline]
    18. 18
  18. Valdes, A. M., S. McWeeney, and G. Thomson. 1997. HLA class II DR-DQ amino acids and insulin-dependent diabetes mellitus: application of the haplotype method. Am. J. Hum. Genet. 60:717-728.[Medline]
    19. 19
  19. Wolford, J. K., and B. Vozarova de Courten. 2004. Genetic basis of type 2 diabetes mellitus: implications for therapy. Treat. Endocrinol. 3:257-267.[CrossRef][Medline]
    20. 20
  20. Zavala, A. V., L. E. Fabiano de Bruno, A. I. Cardoso, A. H. Mota, M. Capucchio, E. Poskus, L. Fainboim, and J. C. Basabe. 1992. Cellular and humoural autoimmunity markers in type 2 (non-insulin-dependent) diabetic patients with secondary drug failure. Diabetologia 35:1159-1164.[CrossRef][Medline]

Clinical and Vaccine Immunology, November 2006, p. 1296-1298, Vol. 13, No. 11
1071-412X/06/$08.00+0     doi:10.1128/CVI.00206-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Almawi, W. Y.
Right arrow Articles by Irani-Hakime, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Almawi, W. Y.
Right arrow Articles by Irani-Hakime, N.

Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»